Leerink Partnrs Has Positive Outlook of TWST Q1 Earnings

Twist Bioscience Co. (NASDAQ:TWST) – Equities researchers at Leerink Partnrs lifted their Q1 2025 earnings estimates for Twist Bioscience in a research report issued on Monday, November 18th. Leerink Partnrs analyst P. Souda now expects that the company will post earnings of ($0.65) per share for the quarter, up from their prior estimate of ($0.71). The consensus estimate for Twist Bioscience’s current full-year earnings is ($2.56) per share. Leerink Partnrs also issued estimates for Twist Bioscience’s Q2 2025 earnings at ($0.62) EPS, Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.34) EPS and FY2026 earnings at ($1.84) EPS.

TWST has been the topic of a number of other reports. JPMorgan Chase & Co. lifted their price target on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. Evercore ISI upped their price target on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Leerink Partners boosted their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Barclays reduced their target price on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research report on Tuesday. Finally, Scotiabank raised their price objective on Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $51.78.

Twist Bioscience Stock Up 1.9 %

TWST stock opened at $41.89 on Thursday. Twist Bioscience has a 52 week low of $23.07 and a 52 week high of $60.90. The firm has a 50-day simple moving average of $43.93 and a 200-day simple moving average of $46.15. The stock has a market capitalization of $2.49 billion, a P/E ratio of -11.57 and a beta of 1.78.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Signaturefd LLC increased its position in Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after acquiring an additional 306 shares during the period. EdgeRock Capital LLC purchased a new stake in Twist Bioscience in the 2nd quarter valued at approximately $43,000. Blue Trust Inc. increased its position in Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after purchasing an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale purchased a new position in Twist Bioscience in the second quarter worth $61,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Twist Bioscience by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after purchasing an additional 381 shares during the period.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 14,334 shares of the stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $639,296.40. Following the sale, the chief executive officer now directly owns 589,552 shares of the company’s stock, valued at approximately $26,294,019.20. This represents a 2.37 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, COO Patrick John Finn sold 10,340 shares of Twist Bioscience stock in a transaction on Monday, November 11th. The stock was sold at an average price of $48.00, for a total transaction of $496,320.00. Following the sale, the chief operating officer now directly owns 221,061 shares of the company’s stock, valued at approximately $10,610,928. This trade represents a 4.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 98,118 shares of company stock valued at $4,391,151. 3.92% of the stock is currently owned by company insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.